M Mitterer
Overview
Explore the profile of M Mitterer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mair M, Mitterer M, Buratti T, Berchtold L, Fong D, Preusser M
ESMO Open
. 2023 May;
8(3):101559.
PMID: 37196399
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has particularly impacted patients with hemato-oncological malignancies, as they showed not only a higher propensity for severe courses but also...
2.
Neubauer T, Brand J, Mitterer M, Hartmann A
Unfallchirurg
. 2019 Jul;
122(7):555-572.
PMID: 31270552
Neurovascular injuries in fractures threaten at least the function of extremities. The timely interaction between diagnosis and treatment of vascular injuries helps to avoid a poor outcome or even fatal...
3.
Seeber A, Mitterer M, Gunsilius E, Mazzoleni G, Giovannetti R, Farsad M, et al.
Oncology
. 2013 Jan;
84(3):186-90.
PMID: 23328311
Objective: Treatment of lung cancer patients is changing rapidly and new treatment options have emerged in recent years. In 2007, to guarantee the best treatment procedure for lung cancer patients...
4.
Fong D, Moser P, Krammel C, Gostner J, Margreiter R, Mitterer M, et al.
Br J Cancer
. 2008 Sep;
99(8):1290-5.
PMID: 18813308
Pancreatic cancer is one of the most devastating human malignancies. Despite considerable research efforts, it remains resistant to almost all available treatment regimens. The human trophoblast cell-surface antigen, TROP2, was...
5.
Steurer M, Spizzo G, Mitterer M, Gastl G
Onkologie
. 2004 May;
27(2):150-4.
PMID: 15138347
Background: Despite recent advances in systemic and supportive therapies, multiple myeloma remains an incurable plasma cell malignancy. Novel therapeutic approaches are thus needed. Thalidomide has recently been recognized as an...
6.
Kabakci K, Hedrich K, Leung J, Mitterer M, Vieregge P, Lencer R, et al.
Neurology
. 2004 Feb;
62(3):395-400.
PMID: 14872019
Background: Most cases of early-onset primary torsion dystonia (PTD) are caused by the same three-base pair (bp) (GAG) deletion in the DYT1 gene. Exon rearrangements are a common mutation type...
7.
Svaldi M, Moroder W, Messner H, Battisti L, Venturi R, Coser P, et al.
J Pediatr Hematol Oncol
. 2002 Jul;
24(5):394-6.
PMID: 12142790
Anewborn with a transient myeloproliferative disorder and a myeloid/natural killer cell leukemia phenotype is described. The blasts expressed CD7, CD33, CD34, CD56, and CD117 but did not react with cytoplasmic...
8.
Svaldi M, Hirber J, Lanthaler A, Mayr O, Faes S, Peer E, et al.
Br J Haematol
. 2001 Nov;
115(1):53-7.
PMID: 11722409
Procalcitonin (PCT) has proven to be a very sensitive marker of sepsis for non-leucopenic patients. Little is known about its relevance in immunosuppressed and leucopenic adults. Four hundred and seventy-five...
9.
Svaldi M, Tappa C, GEBERT U, Bettini D, Fabris P, Franzelin F, et al.
Ann Hematol
. 2001 Sep;
80(7):393-7.
PMID: 11529464
Technetium-99m-sestamibi (MIBI) is a radionuclide tracer taken up by different malignant tumors. A total of 88 MIBI scans were carried out in 20 individuals with monoclonal gammopathy of unknown significance...
10.
Jumaa H, Mitterer M, Reth M, Nielsen P
Eur J Immunol
. 2001 Jul;
31(7):2164-9.
PMID: 11449370
Mice deficient for the adapter protein SLP65 (BLNK) show a partial block in early B cell development, reduced numbers of mature B cells in the periphery, an absence of B1...